Skip to content

January 2026

DMT

What January 2026's 13 new studies found, synthesized from the papers below. All DMT research →

The synthesis

Synthesized from 13 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.

Research published in January 2026 on DMT and related compounds (5-MeO-DMT, ayahuasca alkaloids) spans preclinical, clinical, and theoretical domains. Preclinical studies in rodents and canines suggest potential therapeutic and safety signals—DMT reversed depressive-like behavior and cognitive deficits in stressed mice, and 5-MeO-DMT did not induce seizures in dogs—while a human PET study found a 12.5% increase in global brain glucose metabolism under DMT+harmine. However, evidence is largely preliminary, with small samples, animal models, and theoretical frameworks, and no large-scale clinical trials were reported.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.

Intranasal 5-MeO-DMT produced dose-dependent behavioral signs but no seizures or epileptiform activity on continuous EEG in a canine model.

preclinical animal study Sample size: 11

A single dose of DMT reversed depressive-like behavior and cognitive deficits in stressed mice, outperforming chronic fluoxetine in most domains, and enhanced adult-born granule cell integration.

preclinical animal study

DMT at 1 mg/kg combined with ventral root reimplantation significantly enhanced motor neuron survival, reduced glial reactivity, and upregulated GDNF expression after spinal root avulsion.

preclinical experimental study

A DLLME-LC-MS/MS method successfully quantified DMT and β-carbolines in human hair, with β-carbolines generally detected at higher concentrations than DMT.

method development and validation study Sample size: 6

A time-localized collapse of multifractal spectrum width was temporally locked with selective enhancement of gamma-band power near 43 Hz during peak conscious state transitions, replicable across subjects and conditions.

multi-subject EEG analysis

The review identified 33 studies on 5-MeO-DMT in humans, with most interventional studies using inhalation and showing large heterogeneity in design, dosing, and support.

scoping review Sample size: 33

5-MeO-DMT induced a dissociated state in awake, moving mice characterized by cortical slow oscillations and pupil dilation, with initial REM suppression followed by overcompensation and attenuation of sleep deprivation-induced slow-wave rebound.

observational cohort

Participants reported subjective effects including heightened sensitivity, time distortion, and recall of past experiences, and some said DMT helped resolve personal conflicts or improved a stalled therapeutic process.

qualitative study Sample size: 7

Describes three Brazilian ritual contexts involving DMT preparations and notes that changa, a smokable version, reportedly originated in Australia using acacia as the DMT source.

qualitative

Argues that the reduced predictability of sensory perceptions under psychedelics inclines the brain to interpret perceptions as resulting from non-self-agentic sources, explaining entity encounters.

theoretical or philosophical paper

Proposes that near-death and afterlife experiences are a final endogenous simulation generated by the dying brain, not evidence of metaphysical realms.

theoretical or philosophical paper

Global cerebral glucose metabolism increased by 12.5% under DMT+harmine versus placebo, with widespread cortical increases particularly in higher-order brain networks.

single-blind, crossover design Sample size: 14

Immersion under DMT follows a structured continuum from subtle to gross forms, with perceived presences emerging only after multisensory integration and 3D spatial characteristics have developed.

experimental study with micro-phenomenological interview Sample size: 23

Points of agreement

  • DMT and 5-MeO-DMT show potential therapeutic effects in preclinical models, including antidepressant-like and neuroprotective actions.
  • Human studies indicate DMT alters brain activity and metabolism, with increased glucose metabolism and specific EEG patterns.
  • Subjective experiences under DMT are characterized by immersive and entity encounters, which are structured and reproducible.

Conflicts

  • Preclinical findings in rodents suggest DMT has antidepressant and cognitive benefits, but human clinical evidence remains limited and heterogeneous.
  • Theoretical papers propose mechanistic explanations for psychedelic phenomena, but these are not directly tested against empirical data.

Gaps

  • Durability of effects beyond acute administration is not established.
  • Most studies use small samples or animal models; large-scale human trials are lacking.
  • Blinding and placebo controls are often inadequate, especially in qualitative and EEG studies.
  • Dose-response relationships and optimal routes of administration are not fully characterized.
  • Long-term safety and potential adverse effects in humans remain understudied.
Browse these studies in the library